<div id="readability-page-1"><div><p>(MT Newswires) -- Hubei Jumpcan Pharmaceutical (SHA:600566), through unit Shaanxi Dongke Pharmaceutical, obtained a drug registration certificate from the Chinese drug administration for its lidocaine cataplasms, according to a Shanghai bourse filing on Wednesday.</p><p> The product is an amide local anesthetic that stabilizes nerve cell membranes.</p><p>The certificate is valid until Sept. 8, 2030, the Chinese drug maker said.</p></div></div>

濟川藥業

<p>（MT Newswires）-- 湖北濟川藥業（SHA:600566）通過其子公司陝西東科藥業，獲得了中國藥品監督管理局頒發的利多卡因膏藥的藥品註冊證書，具體信息在週三的上海證券交易所公告中披露。該產品是一種酰胺類局部麻醉劑，能夠穩定神經細胞膜。中國藥企表示，該證書有效期至 2030 年 9 月 8 日</p>

濟川藥業獲得了利多卡因貼劑的註冊證書